ClinVar Miner

Submissions for variant NM_000157.4(GBA):c.1226A>G (p.Asn409Ser) (rs76763715)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 22
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000079336 SCV000224863 pathogenic not provided 2017-05-18 criteria provided, single submitter clinical testing
Courtagen Diagnostics Laboratory,Courtagen Life Sciences RCV000004515 SCV000236536 pathogenic Gaucher's disease, type 1 2015-01-26 criteria provided, single submitter clinical testing
Genetic Services Laboratory, University of Chicago RCV000004515 SCV000247461 pathogenic Gaucher's disease, type 1 2015-02-12 criteria provided, single submitter clinical testing
GeneDx RCV000079336 SCV000321702 pathogenic not provided 2017-04-13 criteria provided, single submitter clinical testing The N409S variant in the GBA gene has been reported previously as the most common pathogenicvariant causing Gaucher disease (GD), particularly among Ashkenazi Jewish individuals due to foundereffect (Zhao and Grabowski, 2002); this variant has been previously reported as N370S due to the useof alternate nomenclature. The N409S variant is almost exclusively associated with thenon-neuronopathic type 1 GD (Liou and Grabowski, 2009). Functional studies of the N409S variantindicate that the defective protein shows reduced activity compared to wildtype (Grace et al., 1994;Malini et al., 2014). Several association studies have also found an over-representation of GBAheterozygotes, including the N409S variant, among patients with Parkinson disease or other Lewybody disorders, particularly those patients with early onset of disease (Moraitou et al., 2011; Nalls etal., 2013; Asselta et al., 2014). The N409S variant is observed in 242/66,666 (0.36%) alleles from individuals of European (non-Finnish) background including one homozygous individual in the ExAC dataset, which is consistent with the high carrier frequency of this pathogenic variant among Ashkenazi Jewish individuals (Lek et al.; Diaz et al., 2000). The N409S variant is a conservativeamino acid substitution, which occurs at a position that is conserved across mammalian species. We interpret N409S as a pathogenic variant.
Illumina Clinical Services Laboratory,Illumina RCV000396221 SCV000348574 pathogenic Gaucher disease 2016-06-14 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000305321 SCV000348575 pathogenic Susceptibility to Parkinson's Disease 2016-06-14 criteria provided, single submitter clinical testing
Counsyl RCV000004515 SCV000485246 pathogenic Gaucher's disease, type 1 2015-12-21 criteria provided, single submitter clinical testing
Centre for Mendelian Genomics,University Medical Centre Ljubljana RCV000414782 SCV000492778 likely pathogenic Rigidity; Akinesia 2014-02-19 criteria provided, single submitter clinical testing
Knight Diagnostic Laboratories,Oregon Health and Sciences University RCV000004515 SCV000538031 pathogenic Gaucher's disease, type 1 2015-07-10 criteria provided, single submitter clinical testing The c.1226A>G (p.Asn409Ser) variant is a known missense variant in a gene where missense is a common mechanism of disease. This variant is very common in the Ashkenazi Jewish population (carrier frequency 41%, Tsuji et al. 1988), and this patient has indeed reported an Ashkenazi Jewish ancestry. In addition, several functional studies have shown this variant to have reduced catalytic activity (by 81-95%) (Babajani et al. 2012). It is found at a very low frequency in control population databases (1000 Genomes, ExAc, and Exome Sequencing Project [ESP]) and has been predicted deleterious by various computational algorithms. It has been reported pathogenic by reputable patient databases (ClinVar, Human Genetic Mutation Database [HGMD] and Emory Genetic Laboratory). In summary, the c.1226A>G (p.Asn409Ser) meets our criteria for a recessive pathogenic variant for Gaucher disease.
Fulgent Genetics,Fulgent Genetics RCV000515439 SCV000611266 pathogenic Lewy body dementia; Gaucher's disease, type 1; Acute neuronopathic Gaucher's disease; Subacute neuronopathic Gaucher's disease; Gaucher disease, perinatal lethal; Gaucher disease type 3C; Parkinson disease, late-onset 2017-05-18 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000079336 SCV000692646 uncertain significance not provided 2017-08-01 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000396221 SCV000697577 pathogenic Gaucher disease 2016-01-18 criteria provided, single submitter clinical testing Variant summary: c.1226A>G affects a conserved nucleotide, resulting in amino acid change from Asn to Ser. 2/3 in-silico tools predict this variant to be benign (SNPs&GO not captured due to low reliability index). This variant was found in 272/123472 control chromosomes at a frequency of 0.0022029, which does not significantly exceed maximal expected frequency of a pathogenic allele (0.005). This variant has been reported in multiple GD pts as well as in pts with Parkinson disease. Functional study showed variant with 13.3% of WT activity (Grace_1994). In addition, multiple clinical laboratories classified this variant as pathogenic. Taken together, this variant was classified as a Pathogenic.
Genomic Research Center, Shahid Beheshti University of Medical Sciences RCV000004515 SCV000746370 pathogenic Gaucher's disease, type 1 2017-12-03 criteria provided, single submitter clinical testing
Invitae RCV000079336 SCV000936391 pathogenic not provided 2018-12-31 criteria provided, single submitter clinical testing This sequence change replaces asparagine with serine at codon 409 of the GBA protein (p.Asn409Ser). The asparagine residue is moderately conserved and there is a small physicochemical difference between asparagine and serine. The frequency data for this variant in the population databases (rs76763715, ExAC) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This variant is a well known variant in individuals affected with Gaucher disease (PMID: 26096741). This variant has also been seen in patients with Parkinson's disease (PMID: 28779532, 25249066, 23676350). ClinVar contains an entry for this variant (Variation ID: 4290). This variant is also known as p.Asn370Ser or N370S in the literature. Experimental studies have shown that this missense change impairs enzyme activity of the GBA protein (PMID: 22592100, 8294487, 22160715). For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000004515 SCV000966812 pathogenic Gaucher's disease, type 1 2019-01-17 criteria provided, single submitter clinical testing proposed classification - variant undergoing re-assessment, contact laboratory
OMIM RCV000004515 SCV000024689 pathogenic Gaucher's disease, type 1 2010-08-01 no assertion criteria provided literature only
OMIM RCV000004516 SCV000024690 risk factor Parkinson disease, late-onset 2010-08-01 no assertion criteria provided literature only
OMIM RCV000004517 SCV000024691 risk factor Dementia, Lewy body, susceptibility to 2010-08-01 no assertion criteria provided literature only
Division of Human Genetics,Children's Hospital of Philadelphia RCV000004515 SCV000238464 pathogenic Gaucher's disease, type 1 2015-03-24 no assertion criteria provided research The GBA variant (c.1226A>G) was identified in many patients in the literature and is a well-known pathogenic variant with phenotypic variability (Tsuji et al. 1988, PMID: 3353383; Fairley et al. 2008, PMID: 18979180; Hruska et al. 2008, PMID: 18338393). The variant is more commonly known as “N370S” reflecting an older nomenclature. Approximately one quarter of all reported type 1 Gaucher disease cases in the International Collaborative Gaucher Group (ICGG) Gaucher Registry are homozygotes for this allele (Fairley et al. 2008, PMID: 18979180). Alleles with this mutation have been shown to have lower activity compared to the wildtype (Grace et al. 1994, PMID: 23510062; Montfort et al. 2004, PMID: 15146461).
GenomeConnect, ClinGen RCV000396221 SCV000607211 not provided Gaucher disease no assertion provided phenotyping only GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000079336 SCV000800925 pathogenic not provided 2017-05-10 no assertion criteria provided clinical testing
GenomeConnect, ClinGen RCV000515439 SCV000986753 not provided Lewy body dementia; Gaucher's disease, type 1; Acute neuronopathic Gaucher's disease; Subacute neuronopathic Gaucher's disease; Gaucher disease, perinatal lethal; Gaucher disease type 3C; Parkinson disease, late-onset no assertion provided phenotyping only Variant interpretted as pathogenic and reported on 04/12/2017 by GTR ID MNG Laboratories. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.